Byondis Initiates Phase I Study of Next Generation Antibody-Drug Conjugate BYON3521

Byondis Initiates Phase I Study of Next Generation Antibody-Drug Conjugate BYON3521 ·        BYON3521 Targets c-MET, Widely Overexpressed in Solid Tumors·        Therapy Uses Proprietary Technologies Designed to Enhance Efficacy...

Related Keywords

,Us Food Drug Administration ,European Medicines Agency ,Conjugation Technology ,Biologics License Application ,Drug Administration ,Marketing Authorization Application ,Dose Escalation ,Maximum Tolerated Dose ,Recommended Dose ,Next Generation Antibody Drug ,Proprietary Linker Drug ,Site Specific Conjugation ,